Susquehanna International Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-19,100
| Closed | -$45K | – | 14257 |
|
|
2022
Q3 | $45K | Buy |
+19,100
| New | +$67.6K | ﹤0.01% | 12276 |
|
|
2022
Q2 | – | Sell |
-25,600
| Closed | -$174K | – | 14378 |
|
|
2022
Q1 | $174K | Buy |
+25,600
| New | +$182K | ﹤0.01% | 11410 |
|
|
2021
Q4 | – | Sell |
-24,200
| Closed | -$180K | – | 14231 |
|
|
2021
Q3 | $180K | Sell |
24,200
-80,500
| -77% | -$499K | ﹤0.01% | 11611 |
|
|
2021
Q2 | $712K | Buy |
104,700
+38,300
| +58% | +$318K | ﹤0.01% | 8701 |
|
|
2021
Q1 | $682K | Buy |
66,400
+30,600
| +85% | +$335K | ﹤0.01% | 8741 |
|
|
2020
Q4 | $251K | Sell |
35,800
-70,700
| -66% | -$550K | ﹤0.01% | 9641 |
|
|
2020
Q3 | $869K | Buy |
+106,500
| New | +$660K | ﹤0.01% | 6466 |
|
|
2020
Q2 | – | Sell |
-12,000
| Closed | -$57K | – | 11202 |
|
|
2020
Q1 | $57K | Sell |
12,000
-3,000
| -20% | -$17.3K | ﹤0.01% | 9619 |
|
|
2019
Q4 | $131K | Buy |
+15,000
| New | +$81.1K | ﹤0.01% | 9016 |
|
|
2019
Q3 | – | Sell |
-11,700
| Closed | -$58K | – | 11032 |
|
|
2019
Q2 | $58K | Buy |
+11,700
| New | +$62.1K | ﹤0.01% | 9811 |
|
|
2018
Q4 | – | Sell |
-41,900
| Closed | -$272K | – | 10257 |
|
|
2018
Q3 | $272K | Sell |
41,900
-28,100
| -40% | -$209K | ﹤0.01% | 7666 |
|
|
2018
Q2 | $536K | Buy |
70,000
+5,200
| +8% | +$75K | ﹤0.01% | 6645 |
|
|
2018
Q1 | $1.45M | Buy |
64,800
+51,400
| +384% | +$1.14M | ﹤0.01% | 4510 |
|
|
2017
Q4 | $171K | Buy |
+13,400
| New | +$197K | ﹤0.01% | 8407 |
|
Other funds holding JNCE
Susquehanna International Group's JNCE Position: Q2 2023 in Review
Susquehanna International Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 108,297 shares — an estimated $200K sold.
Susquehanna International Group first reported a position in JNCE in Q4 2017 and held it in 17 quarters. The position peaked at $2.18M in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Susquehanna International Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Susquehanna International Group sold 108,297 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $200K.
- Susquehanna International Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
- Susquehanna International Group's Jounce Therapeutics, Inc. Common Stock position peaked at $2.18M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.